Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant in Recurrent/Metastatic ER+ Gynecological Malignancies
NCT03926936Phase 2Completed
- Start
- Mar 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of fulvestrant in uterine sarcoma, endometrial carcinoma, sex cord-gonadal stromal tumor (SCST) and 1 more (4 arms). Primary endpoint: Response Rate at 24 weeks. Started Mar 2019; status: completed.
02
Drugs
fulvestrant
03
Conditions
uterine sarcomaendometrial carcinomasex cord-gonadal stromal tumor (SCST)ovarian cancer
Beyond the preview
Go deeper on NCT03926936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926936.